Grenerating a high affinity scorpion toxin receptor in KcsA-Kv1.3 chimeric potassium channels

被引:58
作者
Legros, C
Pollmann, V
Knaus, HG
Farrell, AM
Darbon, H
Bougis, PE
Martin-Eauclaire, MF
Pongs, O
机构
[1] Univ Hamburg, ZMNH, Inst Neurale Signalverarbeitung, D-20246 Hamburg, Germany
[2] Univ Innsbruck, Inst Biochem Pharmakol, A-6020 Innsbruck, Austria
[3] Inst Biol Struct & Microbiol, CNRS, UPR 9039, F-13402 Marseille 20, France
[4] Univ Aix Marseille 2, Fac Med Secteur Nord, Inst Federat Rech Jean Roche, Lab Biochim,CNRS,UMR 6560, F-13916 Marseille 20, France
关键词
D O I
10.1074/jbc.275.22.16918
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The crystal structure of the bacterial K+ channel, KcsA (Doyle, D. A., Morais, C. J., Pfuetzner, R. A., Kuo, A., Gulbis, J. M., Cohen, S. L., Chait, B. T., and MacKinnon, R. (1998) Science 280, 69-77), and subsequent mutagenesis have revealed a high structural conservation from bacteria to human (MacKinnon, R., Cohen, S, L., Kuo, A., Lee, A., and Chait, B. T. (1998) Science 280, 106-109). me have explored this conservation by swapping subregions of the M1-M2 linker of KcsA with those of the S5-S6 linker of the human Kv-channel Kv1.3. The chimeric K+ channel constructs were expressed in Escherichia coli, and their multimeric state was analyzed after purification. We used two scorpion toxins, kaliotoxin and hongotoxin 1, which bind specifically to Kv1.3, to analyze the pharmacological properties of the KcsA-Kv1.3 chimeras. The results demonstrate that the high affinity scorpion toxin receptor of Kv1.3 could be transferred to KcsA. Our biochemical studies with purified KcsA-Kv1.3 chimeras provide direct chemical evidence that a tetrameric channel structure is necessary for forming a functional scorpion toxin receptor. We have obtained KcsA-Kv1.3 chimeras with kaliotoxin affinities (IC50 values of similar to 4 pM) like native Kv1.3 channels. Furthermore, we show that a subregion of the S5-S6 linker may be an important determinant of the pharmacological profile of K+ channels. Using available structural information on KcsA and kaliotoxin, we have developed a structural model for the complex between KcsA-1.3 chimeras and kaliotoxin to aid future pharmacological studies of K+ channels.
引用
收藏
页码:16918 / 16924
页数:7
相关论文
共 31 条
[1]   TOPOLOGY OF THE PORE-REGION OF A K+ CHANNEL REVEALED BY THE NMR-DERIVED STRUCTURES OF SCORPION TOXINS [J].
AIYAR, J ;
WITHKA, JM ;
RIZZI, JP ;
SINGLETON, DH ;
ANDREWS, GC ;
LIN, W ;
BOYD, J ;
HANSON, DC ;
SIMON, M ;
DETHLEFS, B ;
LEE, CL ;
HALL, JE ;
GUTMAN, GA ;
CHANDY, KG .
NEURON, 1995, 15 (05) :1169-1181
[2]   The signature sequence of voltage-gated potassium channels projects into the external vestibule [J].
Aiyar, J ;
Rizzi, JP ;
Gutman, GA ;
Chandy, KG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (49) :31013-31016
[3]   REFINED STRUCTURE OF CHARYBDOTOXIN - COMMON MOTIFS IN SCORPION TOXINS AND INSECT DEFENSINS [J].
BONTEMS, F ;
ROUMESTAND, C ;
GILQUIN, B ;
MENEZ, A ;
TOMA, F .
SCIENCE, 1991, 254 (5037) :1521-1523
[4]   Ion channels in the immune system as targets for immunosuppression [J].
Cahalan, MD ;
Chandy, KG .
CURRENT OPINION IN BIOTECHNOLOGY, 1997, 8 (06) :749-756
[5]   REFINED 3-DIMENSIONAL SOLUTION STRUCTURE OF INSECT DEFENSIN-A [J].
CORNET, B ;
BONMATIN, JM ;
HETRU, C ;
HOFFMANN, JA ;
PTAK, M ;
VOVELLE, F .
STRUCTURE, 1995, 3 (05) :435-448
[6]   Structural dynamics of the Streptomyces lividans K+ channel (SKC1): Oligomeric stoichiometry and stability [J].
Cortes, DM ;
Perozo, E .
BIOCHEMISTRY, 1997, 36 (33) :10343-10352
[7]   The structure of the potassium channel:: Molecular basis of K+ conduction and selectivity [J].
Doyle, DA ;
Cabral, JM ;
Pfuetzner, RA ;
Kuo, AL ;
Gulbis, JM ;
Cohen, SL ;
Chait, BT ;
MacKinnon, R .
SCIENCE, 1998, 280 (5360) :69-77
[8]   A POINT MUTATION IN A SHAKER K+ CHANNEL CHANGES ITS CHARYBDOTOXIN BINDING-SITE FROM LOW TO HIGH-AFFINITY [J].
GOLDSTEIN, SAN ;
MILLER, C .
BIOPHYSICAL JOURNAL, 1992, 62 (01) :5-7
[9]   MECHANISM OF CHARYBDOTOXIN BLOCK OF A VOLTAGE-GATED K+ CHANNEL [J].
GOLDSTEIN, SAN ;
MILLER, C .
BIOPHYSICAL JOURNAL, 1993, 65 (04) :1613-1619
[10]  
GRISSMER S, 1994, MOL PHARMACOL, V45, P1227